Categories: world

Trump to address drug prices in speech, shifting focus to health care before the middle of the election

The administration released a Thursday morning report that highlighted the US government's steady spending on prescription drugs just a few…

The administration released a Thursday morning report that highlighted the US government’s steady spending on prescription drugs just a few hours before President Trump was released to speak at the Department of Health and Human Services for the first time and less than two weeks from the half-year’s election, where healthcare plays a crucial role.

A report from HHS compares the prices Medicare paid for 27 prescription drugs with the average prices for the same drugs of countries with similar economic conditions. The conclusion that the higher US prices mean that Medicare pays almost twice as much as the program would pay for the same or similar drugs in other countries.

“Medicare could achieve significant savings if US prices were similar to other major market-based economies,” concludes the report.

Drug prices and the theme of freeloading by foreign governments paying significantly less for drugs, although developed within the United States, are expected to play a central role in Trump’s address.

It represents the next leg in his management’s endeavor to work hard on the pharmaceutical industry. The Medicare program, which covers 55 million older and disabled Americans, is responsible for 29 percent of the nation’s prescription drug.

In a series of twitter’s Thursday morning, HHS secretary Alex Azar referred to Trump’s previous criticism of other governments paying significantly less for drugs than the US government. The United States is the largest research and development fund in the pharmaceutical sector, but lacks negotiating power to lower prices – unlike countries with public health programs.

The report “gives worrying insight into how today’s international drug pricing system has put America in the end,” Azar tweeted.

The president focuses on health care at the start of the mid-term elections where democracies have hampered Republicans for their failed attempts last summer to revoke and replace the Affordable Care Act, a team that Trump has strongly criticized. His administration has been working to chip off several ACA requirements, and the Democrats argue that Republicans are not interested in protecting people with existing health conditions and ensuring that they receive healthcare at affordable costs.

Trump has fake tweeted “All Republicans” support to protect people with existing conditions. Republicans did not support ACA’s 2010 passage, which adopted them, and the majority of them voted to cancel and replace Obamacare last year.

Trump also signed sweeping legislation at the White House on Wednesday due to the Opioid crisis, although some experts say it’s just a first step.

The 19-page HHS report specifically looks at drugs purchased and dispensed by doctors themselves, under Medicare’s Part B program. Earlier, Azar has targeted the specific part of the program as part B spending has grown much faster than drug-administered drugs under Medicare’s Part D program.

While part B spending on drugs has doubled since 2006, shared D spending on drugs has risen much slower. Reports Notes Part B is not subject to restrictions on the drugs covered, which means there is no incentive to reduce costs.

Both protect people with previously existing conditions and lower prescription drug prices are high among the voters’ affairs that lead in elections. In a review in March, the Kaiser Family Foundation said eight out of ten respondents said drug costs were unreasonable and 92 percent said that regulatory approval to reduce the cost of prescription drugs should be an important or important priority.

Trump started its drug cost initiative by May of the White House Rose Garden, announcing a 44-page drawing that contains some important ideas that could threaten industries along the drug supply chain.

The May president also argued that drug companies would announce “massive” voluntary price cuts. When Pfizer and Novartis were announced in the summer, they withdraw from any planned price increases. Trump considered it as proof of how his print tactics worked.

The administration has moved twice a month to provisions aimed at lowering the drug. Trump signed a bill that prohibited so-called “gag clauses” as forbidden doctors from telling patients when they could save money by paying in cash or trying to get a cheaper alternative medicine. Last week, Azar proposed a rule that requires companies to list in television ads the price of a 30-day delivery or treatment for the drug they are trying to sell.

Published by